Navigation Links
New, Published GELNIQUE Data Show Efficacy, Convenience and Excellent Tolerability
Date:3/16/2009

CORONA, Calif., March 16 /PRNewswire-FirstCall/ -- New Phase 3 data, published in the April issue of The Journal of Urology, show that GELNIQUE(TM) (oxybutynin chloride) Gel 10%, the first and only topical gel approved for the treatment of overactive bladder (OAB), is effective at improving the symptoms of urge urinary incontinence, urgency and frequency, and is extremely well tolerated in adults.

GELNIQUE is a quick drying, clear and colorless, fragrance-free gel containing oxybutynin hydrochloride developed and marketed by Watson (NYSE: WPI), a leader in generic and specialty branded pharmaceuticals. Because the active ingredient in GELNIQUE is delivered transdermally, it is not metabolized by the liver in the same way as orally administered oxybutynin. This unique dosing results in a low level of side effects, such as dry mouth and constipation.

"The study data reveal that this innovative gel formulation provides the highly desired combination of efficacy and tolerability when utilized to treat symptoms of overactive bladder," said David R. Staskin, MD, associate professor of urology at Tufts University School of Medicine and Caritas - St. Elizabeth's Medical Center and lead author of the study. "GELNIQUE has the potential to be a very important option for the treatment of patients who suffer from problems with bladder control."

Clinical Data

The double-blind, placebo-controlled study included 789 men and women with urge-predominant urinary incontinence (UI) from 76 clinics across the U.S. Patients reported a mean 5.4 daily UI episodes and a mean daily urinary frequency of 12.2-12.4. The majority of participants were women (89.2 percent).

Patients were randomized to receive either 1 gram of GELNIQUE (n=389) or a matching placebo gel (n=400) once daily for 12 weeks. GELNIQUE delivers a consistent dose of oxybutynin through the skin over a 24-hour period. A 1- gram (approx. 1 mL) daily dose delivers about 4 mg oxybutynin each day. Patients applied GELNIQUE each day to rotating sites on the abdomen, upper arm or shoulder and thigh.

By week 12, the mean number of episodes of urinary incontinence, the study's primary endpoint, decreased significantly (p<0.0001) more in patients treated with GELNIQUE (.3.0/day) than in those given placebo (.2.5/day). Treatment with the oxybutynin topical gel also produced a significantly greater (p=0.0017) decrease in mean urinary frequency as well as a significantly greater (p=0.0018) increase in voided volume (.2.7/day and 21.0 mL, respectively) versus placebo (.2.0/day and 3.8 mL).

Treatment with GELNIQUE was well tolerated with no serious treatment-related adverse events. Overall, nearly 89 percent of patients in both treatment groups completed the double-blind treatment; discontinuation due to drug-related adverse events was uncommon at 1.8 percent in both active treatment and placebo groups. Dry mouth was the most common side effect with GELNIQUE, occurring in about 7 percent of participants, versus about 3 percent in the placebo group.

Few patients in either group experienced application-site skin reactions (5.4 percent with GELNIQUE and 1.0 percent with placebo). Only 3 of 389 patients (0.8 percent) treated with GELNIQUE and 1 of 400 (0.3 percent) given placebo discontinued treatment due to skin reactions. There was no severe erythema observed in the trial.

Additional pharmacology studies showed that showering one hour or later, or the application of sunscreen 30 minutes before or after GELNIQUE application did not significantly alter the absorption of the drug.

For full prescribing information, please visit www.gelnique.com.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a global leader in the development and distribution of pharmaceuticals with a broad portfolio of generic products and a specialized portfolio of branded pharmaceuticals focused on Urology, Gynecology and Nephrology (medical).

In the U.S., the Watson portfolio includes GELNIQUE(TM), RAPAFLO(TM), Oxytrol(R); Ferrlecit(R), INFeD(R), TRELSTAR(R) LA; and TRELSTAR(R) Depot. In addition, Watson markets the following brands under co-promotion agreements: AndroGel(R), with Solvay Pharmaceuticals, Inc.; Tri-Luma(R) Cream, with Galderma Laboratories; and Femring(R), with Warner Chilcott Limited. The Watson pipeline portfolio includes a number of products, including a six-month formulation of TRELSTAR(R), for the treatment of advanced prostate cancer which is currently under review by the FDA; URACYST(R), under development for cystitis; and a novel new oral contraceptive.

For press releases and other company information, visit the Watson website at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the impact of competitive products and pricing; market acceptance of and continued demand for Watson's products, including GELNIQUE; difficulties or delays in manufacturing; the difficulty of predicting the timing or outcome of FDA or other regulatory agency approvals or actions, if any; patents and other intellectual property rights held by the Company and the ability to successfully enforce such rights against third parties; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2008.

    CONTACTS:
    Watson Pharmaceuticals, Inc.      Ogilvy Public Relations
    Patty Eisenhaur                   Lori Schachtman
    (951) 493-5611                    (847) 975-2330

'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
2. Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion
3. Nebivolol Lowers Blood Pressure in Mild-to-Moderate Hypertensive Patients as Demonstrated in a Study Published in the Journal of Clinical Hypertension
4. Results from Study Evaluating PROCRIT(R) in Intensive Care Unit Patients Published in New England Journal of Medicine
5. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
6. Study Published in Endocrinology Reports Potential of Modigene Technology to Extend Duration of Protein Drugs
7. New Data Published in Neurology Show Once-Daily Lamictal XR Significantly Reduced Partial Seizures in Patients with Epilepsy
8. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
9. Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
10. UPDATE: Nebivolol Lowers Blood Pressure in African Americans With Stage I-II Hypertension as Demonstrated in a Study Published in the Journal of Clinical Hypertension
11. Tumor Eradication Article Published by Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... Forecast to 2022" report to their offering. ... the patients with kidney failure, it replaces the function of ... patient,s blood and thus the treatment helps to keep the ... balance. Increasing number of ESRD patients & ...
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... RIDGE, Ill. and INDIANAPOLIS ... of students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship ... The 2016 scholarship winners, announced today online at ... to let type 1 diabetes stand in the way ... Diabetes has supported the Foundation,s scholarship program since 2012, ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. ... The attorneys chosen by their peers for this recognition are considered among the top ... Shareholders received special honors as members of this year’s Legal Elite Hall of Fame: ...
Breaking Medicine News(10 mins):